viewCB2 Insights Inc.

CB2 Insights launches medical cannabis industry’s first interactive dashboard to offer patient insights

The dashboard is free, accessed via the firm's website, and offers key patient insights derived from the firm's clinical operations

CB2 Insights Inc. -
Tom Brogan, director at CB2 Insights said: "Accurate, structured data is at the center of everything healthcare companies do in this day and age"

CB2 Insights Inc (CSE:CBII) (OTMKTS:CBIIF), the medical cannabis research, data and education group, has extended the reach of its business with the launch of a new interactive dashboard for use by stakeholders.

The dashboard, accessed via the firm's website at https://cb2insights.ca/data, is free, and offers key patient insights derived from the firm's clinical operations.

It was created to answer hundreds of questions from global industry stakeholders, including government agencies and major research groups. It also allows users to submit additional data requests directly to CB2's research and data team.

READ: CB2 Insights bolsters board with healthcare data expert

"This new interactive tool will allow these groups to access the primary insights that they are requesting quickly and gain real-time results," Prad Sekar, the company's CEO, said in a statement.

"But with the millions of data points that we monitor, they also have the opportunity to discuss with us how they can receive more tailored results that match their needs. And more importantly, solidify CB2 Insights as one of the sole providers of these types of insights in this industry."

Tom Brogan, director at CB2 Insights added; "Accurate, structured data is at the center of everything healthcare companies do in this day and age. Access to the type of medical cannabis data that CB2 holds is not only rare, it is essential to truly transition these alternative treatments into mainstream healthcare. This new tool is certainly a powerful bridge to expedite that process across a wide range of industry stakeholders."

CB2 Insights owns one of the largest group of multi-state medical cannabis evaluation and education centers and operates in states such as Colorado, Massachusetts, Maryland, New Jersey, Pennsylvania, Connecticut and Maine.

Over 100,000 patients

Physicians, nurse practitioners and cannabis educators treat and support more than 100,000 patients each year across 60 different primary conditions.

With high patient diversity seeking treatment for everything from chronic pain to sleep disorders to anxiety and depression, CB2 Insights has access to anonymized and de-identified insights into one of the world’s largest and richest data sets derived from the point-of-care.

CB2 also offers comprehensive contract research organization (CRO) services including full-scale clinical trial management, trial design, monitoring and other key research functions used by licensed producers, multi-state operators and traditional pharmaceutical companies entering the medical cannabis space.

Shares in CB2 Insights added over 13% to stand at C$0.085 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Quick facts: CB2 Insights Inc.

Price: 0.18 CAD

Market: CSE
Market Cap: $17.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...


Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read